Compositions and methods for treating bladder dysfunction
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsImre Kifor, Gordon Williams, Maryrose P. Sullivan
Life of this patent
Estimating the term…
Abstract
A method for treating patients having bladder dysfunction is described. The method involves the step of treating a patient with a renin-angiotensin system inhibitor. Preferably the inhibitor is an Angiotensin II antagonist, an ACE inhibitor, or a renin inhibitor. Compositions of a combination of an AT1 specific Angiotensin II antagonist and an Angiotensin II agonist are also described. The compositions are useful for treating bladder dysfunction.
Claims28
A method for treating bladder dysfunction in a subject, comprising:
- administering to a subject exhibiting symptoms of bladder dysfunction an effective amount of a renin-angiotensin system inhibitor to decrease symptoms of bladder dysfunction, and wherein the amount is one which modifies acutely systemic blood pressure of the subject by less than 10%.
A method for preventing bladder dysfunction in a subject, comprising:
- administering to a subject at risk of developing bladder dysfunction an effective amount of a renin-angiotensin system inhibitor to prevent bladder dysfunction, and wherein the amount is one which modifies acutely systemic blood pressure of the subject by less than 10%.
A method for treating bladder hypertrophy and remodeling in a subject, comprising:
- administering to a subject having bladder hypertrophy and remodeling an effective amount of a renin-angiotensin system inhibitor to reduce bladder hypertrophy and remodeling, and wherein the amount is one which modifies acutely systemic blood pressure of the subject by less than 10%.
A method for treating bladder dysfunction in a subject comprising:
- administering to a subject exhibiting symptoms of bladder dysfunction, an effective amount of an AT1 specific Angiotensin II antagonist and an Angiotensin II agonist to decrease the symptoms of bladder dysfunction.
A method for reducing the risk of acquiring bladder dysfunction in a subject comprising:
- administering to a subject at risk of developing bladder dysfunction, an effective amount of an AT1 specific Angiotensin II antagonist and an Angiotensin II agonist to reduce the risk of acquiring bladder dysfunction.
A method for treating bladder hypertrophy and remodeling in a subject comprising:
- administering to a subject having bladder hypertrophy and remodeling, an effective amount of an AT1 specific Angiotensin II antagonist and an Angiotensin II agonist to reduce bladder hypertrophy and remodelling.
A pharmaceutical composition, comprising:
- an AT1 specific Angiotensin II antagonist,
- an Angiotensin II agonist, and
- a pharmaceutically acceptable carrier, wherein the AT1 specific Angiotensin II antagonist and the Angiotensin II agonist are present in an effective dose for treating bladder dysfunction.
Dependencies are inferred from the claim text.